March 10, 2025

CRISPR & Cas Genes Market Size Reach USD 17.49 Billion by 2034

The global CRISPR & Cas genes market size was calculated at USD 3.67 billion in 2024 and is expected to reach around USD 17.49 billion by 2034, growing at a CAGR of 16.90%.

CRISPR and Cas Genes Market Size 2025 to 2034

Get Sample Copy of Report@ https://www.precedenceresearch.com/sample/1108

Key Points

  • In 2024, North America held the highest market share of 39%, leading the global market.
  • Asia Pacific is anticipated to witness the most significant growth rate in the coming years.
  • The biomedical segment was the top revenue-generating application in 2024.
  • The product segment led the market in terms of revenue share within the product & service category.
  • The biotechnology and pharmaceutical sector contributed the highest market share among end-users.

Drivers

The rapid advancements in genome editing technologies, particularly CRISPR, have revolutionized the field of molecular biology, driving significant market growth. The increasing prevalence of genetic disorders and infectious diseases has intensified the demand for CRISPR-based therapeutic solutions.

Additionally, government initiatives supporting research in gene editing and biotechnology are fueling market expansion. The integration of artificial intelligence (AI) and machine learning in CRISPR applications is further enhancing its precision and efficiency, making it a preferred choice for genetic research.

Opportunities

The expanding applications of CRISPR in regenerative medicine and drug discovery are creating new market opportunities. The rise of gene therapy for conditions such as sickle cell anemia, cystic fibrosis, and muscular dystrophy is expected to drive further advancements in CRISPR-based treatments.

Additionally, the agricultural sector is leveraging CRISPR technology to improve crop yields, disease resistance, and food security, broadening its commercial potential. The rise in venture capital investments and strategic partnerships among biotech firms are also fostering innovation in this market.

Challenges

One of the key challenges faced by the CRISPR & Cas genes market is the lack of a globally uniform regulatory framework. Varying regulations across different regions create complexities in product approvals and market entry.

Ethical concerns regarding germline editing and the potential misuse of CRISPR technology also present hurdles to widespread adoption. Moreover, the risk of off-target effects, which can cause unintended genetic changes, poses a challenge for researchers and healthcare professionals aiming for precise genome modifications.

Regional Analysis

North America dominates the market due to the presence of advanced research institutions, well-established biotech firms, and significant funding for gene-editing projects. Europe is also a key player, benefiting from increasing investments in genomic medicine and growing regulatory support for genetic research.

The Asia-Pacific region is expected to witness the fastest growth, driven by rising government funding, expanding biotech industries, and growing awareness of genetic therapies. Latin America and the Middle East & Africa are slowly gaining traction in the market, with increased investments in healthcare infrastructure and research initiatives.

CRISPR & Cas Genes Market Companies

  • Caribou Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Cellectis
  • AstraZeneca
  • Editas Medicine, Inc.
  • Addgene
  • Egenesis
  • Horizon Discovery Group Plc
  • Intellia Therapeutics, Inc.
  • Genscrip
  • Danaher Corporation
  • Lonza
  • Merck KGaA
  • Synthego
  • Mammoth Biosciences
  • Inscripta, Inc.
  • Cibus
  • New England BioLabs
  • Takara Bio, Inc.

Segments Covered in the Report

By Product & Service

  • By Service
    • Microbial Gene Editing
    • Cell Line Engineering
    • gRNA Design
    • DNA Synthesis
  • By Product
    • Design Tool
    • Kits & Enzymes
    • Libraries
    • Antibodies
    • Others

By Application

  • Agricultural
  • Biomedical
    • Functional Genomics
    • Genome Engineering
    • Disease Model Studies
    • Epigenetics
    • Others

End-use Outlook

    • Contract Research Organizations (CROs),
    • Academics & Government Research Institutes
    • Biotechnology & Pharmaceutical Companies

By Regional Outlook

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Middle East & Africa
  • Latin America

Ready for more? Dive into the full experience on our website@ https://www.precedenceresearch.com/